Reslizumab
Common brand names: CinqairThis medication is used along with other medications to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma.
May Treat: Eosinophilic asthma
Brand Names: Cinqair
Drug Class: Asthma Therapy - Interleukin-5 (IL-5) Inhibitors, MAb
Availability: Prescription Required
Pregnancy: Consult a doctor before using
Lactation: Consult a doctor before using
PrecautionsFor informational purposes only. Consult a medical professional for advice.
Source: First Databank Learn more
CINQAIR® (reslizumab) Injection – About Asthma …
CINQAIR is an anti-IL-5 medication that reduces severe, uncontrolled eosinophilic asthma attacks and improves breathing and quality of life. Learn how to get CINQAIR, its cost support program, and its possible side …
Reslizumab - Wikipedia
Reslizumab, sold under the brand names Cinqair and Cinqaero, is a humanized monoclonal antibody against human interleukin-5 (IL-5). Reslizumab binds specifically to IL-5, a key cytokine responsible for the differentiation, maturation, recruitment and activation of human eosinophils. By binding to human IL-5, it blocks its biological function; consequently survival and activity of eosinophils are reduced. The benefits with reslizumab are its ability to reduce the exacerbation r…
Wikipedia · Text under CC-BY-SA license- Estimated Reading Time: 8 mins
Reslizumab Uses, Side Effects & Warnings - Drugs.com
Reslizumab is an intravenous medicine for severe asthma in adults. It reduces a type of white blood cell that may contribute to asthma symptoms. Learn about its …
- Reslizumab is used together with other medicines to help control severe asthmain adults. Reslizumab affects your immune system, reducing levels of a certain type of white blood cell th…
- 8.6/10(7)
Reslizumab (intravenous route) - Mayo Clinic
Reslizumab injection is used with other medicines for the maintenance treatment of severe asthma in patients with an eosinophilic phenotype. This medicine may reduce blood …
Reslizumab (Cinqair) - NCBI Bookshelf - National …
Reslizumab is a humanized immunoglobulin G (IgG)4 kappa monoclonal antibody that binds to human interleukin-5, thereby reducing the production and survival of eosinophils.
CINQAIR® (reslizumab) Injection – About CINQAIR
CINQAIR is an anti-IL-5 medication that reduces eosinophils and inflammation in the airways. It is given once every 4 weeks by a healthcare provider and may help prevent asthma attacks, improve breathing, and quality …
Reslizumab (Cinqair) for Eosinophilic Asthma - AAFP
Nov 15, 2017 · Reslizumab is a monoclonal antibody that blocks interleukin-5 and reduces eosinophils in severe asthma. It costs $905 per month and requires intravenous infusion …
FDA approves Cinqair to treat severe asthma | FDA
Cinqair is a monoclonal antibody that reduces blood eosinophils and severe asthma attacks. It is administered every four weeks by infusion and can cause serious side effects …
Reslizumab: Uses, Interactions, Mechanism of Action
172 rows · Mar 19, 2008 · Reslizumab is a monoclonal antibody that blocks the action of IL-5, a cytokine that promotes eosinophil growth and survival. It is approved for adults with severe asthma with high eosinophil levels and …
Reslizumab Advanced Patient Information - Drugs.com
May 9, 2024 · Detailed drug Information for Reslizumab. Includes common brand names, drug descriptions, warnings, side effects and dosing information.
Skip to content
